Highest-materiality recent filing
KORU Medical shareholders approve all proposals at 2026 annual meeting
All seven director nominees elected with over 97% of votes cast.
KORU Medical Q1 revenue $11.8M (+22% YoY); net loss improves to $0.8M; FY guidance reiterated
Net revenue $11.8M, up 22% YoY; domestic core +11.7%, international core +35.2%, pharma services +166%.
KORU Medical amends HSBC credit facility, extends maturities and lowers rate floor
Amendment extends $5M revolver maturity from Dec 31, 2026 to Mar 30, 2028.
CEO Linda Tharby to retire June 2026; Adam Kalbermatten named successor
Tharby retires as CEO effective June 30, 2026; will serve as advisory employee through Dec 31, 2026.
KORU Medical reports 22% FY2025 revenue growth; positive adjusted EBITDA; initiates FY2026 guidance
Q4 2025 net revenue $10.9M (+23% YoY); FY2025 net revenue $41.1M (+22% YoY).
KORU Medical amends bylaws to enhance stockholder nomination procedures
Board unanimously adopted amended bylaws effective Feb 5, 2026.
Preliminary Q4 2025 net revenue $10.9M, up 23% YoY; full year net revenue $41.1M, up 22% YoY.
KORU Medical restates manufacturing/supply pact with Command Medical through 2026
Amended and Restated Manufacturing and Supply Agreement with Command Medical Products, effective Jan 1, 2024.
KORU Medical Q3 revenue $10.4M (+27% YoY), raises full-year guidance
Q3 net revenues $10.4M, up 27% YoY; core business (domestic + international) $9.8M, up 30%.
KORU Medical Q2 revenue up 21% to record $10.2M; raises FY 2025 revenue guidance
Q2 2025 net revenue of $10.2 million, +21% YoY; Core revenue $9.3M (+19%), PST $0.9M (+42%).
KORU Medical Systems shareholders elect all director nominees at 2025 annual meeting
All seven nominees elected; votes 'for' ranged from 23.5M to 23.9M of 23.95M cast (excl. broker non-votes).
KORU Medical reports record Q1 revenue of $9.6M, up 18% YoY; raises FY2025 guidance
Core revenue (Domestic + International) grew 21% YoY to $9.4M; International up 35.6%.
KORU Medical CCO resigns; FY2025 revenue guidance reiterated at $38-39M
Kenneth Miller resigned as Chief Commercial Officer effective April 3, 2025, to become CEO at a non-competing firm.
KORU Medical amends loan agreement, extends credit facility maturity to Dec 2026
Amendment extends $5M revolving credit facility maturity to Dec 31, 2026; term loan interest-only period to Oct 1, 2026.
KORU Medical reports record Q4 revenue of $8.8M (+23% YoY); issues 2025 guidance $38-39M
Q4 net revenue $8.8M (+23% YoY); full year $33.6M (+18% YoY).
KORU Medical reports record Q4 revenue $8.9M (+23% YoY); positive cash flow in Q4
Preliminary full-year 2024 net revenue of $33.7M, up 18% YoY; Q4 revenue $8.9M, up 23% YoY.
KORU Medical Q3 revenue $8.2M (+17% YoY); raises FY 2024 guidance
Q3 net revenue $8.2M, up 17% YoY; gross margin 63.4%, up 140 bps from 62.0%.
KORU Medical Systems adopts LTIP; grants up to 434,489 PSUs plus RSUs and options to execs
LTIP approved; equity awards granted to CEO Tharby (63,872 RSUs, 127,660 PSUs, 140,950 options) and other named execs.
KORU Medical Q2 revenue record $8.4M, up 22%; raises FY2024 guidance
Q2 net revenues of $8.4M, a 22% YoY increase; core business grew 20% driven by SCIg market growth and share gains.
KORU Medical appoints Christopher Pazdan as COO, eliminates CTO role held by Brian Case
Christopher Pazdan appointed Chief Operating Officer, effective July 18, 2024, from SVP Operations.
Koru Medical dismisses MMQ as auditor, engages Cherry Bekaert
Audit Committee dismissed McGrail Merkel Quinn & Associates (MMQ) effective June 3, 2024.
Koru Medical Systems reports 2024 annual meeting results; all proposals passed
Elected all 7 director nominees: Fletcher, Cascella, French, Manko, Matin, Tharby, Wholihan.
KORU Medical Q1 revenue up 11% to $8.2M; gross margin expands 620bps to 62.3%
Net revenues of $8.2M, +10.9% YoY; Core business grew 13.6%, driven by 63% International increase.
KORU Medical wins EU notified body appeal, CE certification continues uninterrupted
BSI had recommended against continued certification after March 2024 audit nonconformance.
KORU Medical reports Q4 rev $7.2M, FY net loss $13.7M; guides 2024 rev $31.2-32.2M
Q4 net revenues $7.2M (-2% YoY); gross margin improved to 60.3% (+470bps).
On April 3, 2025, Kenneth Miller resigned his employment and position as Chief Commercial Officer of KORU Medical Systems, Inc. (the “Company”), effective immediately, to pursue a Chief Executive Officer role at an organization that does not compete with the Company.
On July 18, 2024, the Company’s Board of Directors eliminated the position of Chief Technology Officer, currently held by Brian Case, effective as of September 16, 2024. Mr. Case’s employment with the Company will terminate concurrently with elimination of that position.
Max materiality 0.75 · Median 0.60 · Most common event earnings